At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, reviews the development of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) signalling pathway and the identification of predictive biomarkers of response to immunotherapies for the management of patients with lung cancer.
Immune checkpoint inhibitors and biomarker-driven strategies for managing lung cancer
26th August 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?